Founder & Chief Executive Officer, Royalty Pharma
Mr. Legorreta founded Royalty Pharma in 1996. Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property, with over $15 billion in royalty assets. Royalty Pharma funds innovation in life sciences, indirectly, when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors) or, directly, when it partners with life sciences companies to co-develop and co-fund products in late-stage human clinical trials. Prior to founding Royalty Pharma, Mr. Legorreta spent a decade at Lazard Frères in Paris and New York where he provided cross-border merger and acquisition and corporate finance advisory services to European and U.S. corporations. Mr. Legorreta serves on the Board of Governors of the New York Academy of Sciences, and the Boards of Trustees of the Hospital for Special Surgery, the Pasteur Foundation (U.S. affiliate of the French Institut Pasteur), The Open Medical Institute, The Park Avenue Armory and Grace Church School. Mr. Legorreta founded and is currently Chairman of Alianza Médica para la Salud (AMSA), a privately-funded, not-for-profit foundation whose goal is to educate Latin American doctors and healthcare providers to improve the quality of healthcare in Latin America. Mr. Legorreta received a degree in industrial engineering from Universidad Iberoamericana (Mexico City).
Executive Vice President and Chief Financial Officer
Ms. Gray joined Royalty Pharma in January 2005 after a fourteen year career in investment banking. At Royalty Pharma, Ms. Gray has led the Company’s efforts to maximize its financial capabilities. She spearheaded the Company’s successful implementation of a $2.3 billion credit facility in 2007 and has helped raise over $1.4 billion in equity capital for the Company. Ms. Gray was a managing director and the senior analyst covering the healthcare sector for CIBC World Market's high yield group from 2002 to 2004. She worked in a similar capacity at Merrill Lynch prior to joining CIBC World Markets. Ms. Gray joined Merrill Lynch in April 1999 after nine years at Chase Securities (a predecessor of JP Morgan), working in various capacities within the high yield and the structured finance groups. Ms. Gray received a BA with honors from Wesleyan University and holds an MBA degree from Columbia University.
Executive Vice President, Head of Research & Investments
Dr. Reddoch joined Royalty Pharma in July 2008 after twelve years on Wall Street as a biotechnology analyst. Prior to joining Royalty Pharma, Dr. Reddoch was Managing Director and Head of Healthcare Equity Research at Friedman Billings Ramsey. He previously worked at Bank of America and CIBC World Markets Corp (now Oppenheimer & Co). Dr. Reddoch holds a BA from Furman University and a PhD in biochemistry and molecular genetics from the University of Alabama at Birmingham. He was a postdoctoral fellow at the Yale University School of Medicine.
Executive Vice President, Investments & General Counsel
Mr. Lloyd joined Royalty Pharma in 2011 after representing Royalty Pharma on all transactional work since 2006. Prior to joining Royalty Pharma, Mr. Lloyd was a partner in Goodwin Procter’s Private Equity Group and co-head of the M&A group at Testa, Hurwitz & Thibeault. Mr. Lloyd began his career at Davis Polk & Wardwell in New York and Paris. In 2002-2003, Mr. Lloyd worked in Hong Kong as the Chief Financial Officer and General Counsel of the Asian operations of an education and travel company. Mr. Lloyd received an AB from Princeton University and a JD degree from New York University Law School, where he was on the Law Review.
Chief Administrative Officer and Chief Compliance Officer
Mr. Erb has 25 years of experience in risk management and information technology in the investment management industry. Prior to joining Royalty Pharma, Mr. Erb served as Chief Operating Officer and Chief Technology Officer at SuttonBrook Capital Management, an alternative investment partnership, which he co-founded. Prior to SuttonBrook, Mr. Erb was also Chief Operating Officer and Chief Technology Officer at Highbridge Capital Management, where he was solely responsible for the worldwide formation of the firms offices and the design, selection and management of all technology employed by the firm, including communication infrastructures, and front, middle and back office systems. Additionally, he had worldwide responsibility for operational risk control, disaster planning recovery and co-responsibility for day-to-day operations.
Vice President, Research & Investments
Dr. Chiaramonte joined Royalty Pharma in January 2008. From 2006 to 2008, Dr. Chiaramonte worked as a biotechnology equity research associate at Jefferies & Company. From 2002 to 2006, she was a post-doctoral fellow in the Department of Biochemistry and Molecular Genetics at the University of Colorado Health Sciences Center. Dr. Chiaramonte received a BA in mathematics, summa cum laude, from Providence College; an MA in mathematics from the University of Colorado; and a PhD in chemistry (Biochemistry Program) from the University of Colorado.
Vice President, Research & Investments
Mr. Coyne joined Royalty Pharma in 2010. Prior to joining Royalty Pharma, Mr. Coyne worked as a biotechnology equity research associate, and most recently as a senior analyst at JP Morgan from 2007 to 2010. From 2006 to 2007, he worked as a biotechnology equity research associate at Rodman & Renshaw. Prior to this, Mr. Coyne worked in various commercial roles at Wyeth Pharmaceuticals. Mr. Coyne received a BS in business administration from La Salle University and an MBA from La Salle University.
Vice President, Research & Investments
Dr. Urist joined Royalty Pharma in 2013. Prior to joining Royalty Pharma, Dr. Urist worked Morgan Stanley in equity research from 2005 to 2013, most recently as Executive Director and the senior biotechnology analyst. Earlier at Morgan Stanley, he covered the life science tools and diagnostics sectors, where he was recognized in Institutional Investor’s All-America Research Team. Dr. Urist graduated Phi Beta Kappa from Johns Hopkins University and holds a MD and PhD from Columbia University.
Vice President, Finance
Mr. Rielly joined Royalty Pharma in 1999. From December 1997 to May 1999, Mr. Rielly was the Vice President of Finance, Treasurer and Secretary of Cadus Pharmaceutical Corporation, a publicly traded biotechnology company. Mr. Rielly joined Cadus Pharmaceutical Corporation as its Controller in September 1992. From November 1989 to September 1992, Mr. Rielly was the Controller and Treasurer for Baring Brothers & Company Ltd, an investment banking firm. Mr. Rielly is a certified public accountant and holds a BSBA from Bucknell University.
Vice President, Investor Relations & Public Affairs
Mr. von Perfall joined Royalty Pharma in 2009. Prior to joining Royalty Pharma, Mr. von Perfall was the Co-Founder and Chief Network Officer of XTF, a start-up exchange traded fund ratings agency. Mr. von Perfall started his career as a talent scout with BMG Entertainment where he oversaw the artistic development of a number of critically and commercially successful recording artists, followed by corporate venturing positions with Bertelsmann AG where he initiated and oversaw early stage investments in IP based media and entertainment companies. Following Bertelsmann, Mr. von Perfall served in an advisory role for the International Finance Corporation/World Bank Group where he acted as value proposition expert for the syndication of media sector investments. Mr. von Perfall attended the Hochschule St. Gallen in Switzerland and holds a BA in politics from the University of San Francisco and an MBA from the Stern School of Business at New York University.
Senior Associate, Research & Investments
Ms. Klymkowsky joined Royalty Pharma in 2012. Prior to joining Royalty Pharma, Ms. Klymkowsky was an Analyst in the Healthcare Investment Banking group at Goldman, Sachs & Co in New York. Ms. Klymkowsky holds a BA in Molecular, Cellular and Developmental Biology and a BSBA from the University of Colorado at Boulder.
Ms. Lechleiter joined Royalty Pharma in 2014. Prior to joining Royalty Pharma, Ms. Lechleiter was an Associate in the Healthcare Investment Banking group at J.P. Morgan. Ms. Lechleiter holds BS degrees in Finance and Accounting and a BA in Spanish from Miami University.
Associate, Research & Investments
Ms. Kugler joined Royalty Pharma in 2014. Prior to joining Royalty Pharma, Ms. Kugler worked as a biotechnology equity research Senior Associate at Morgan Stanley. Ms. Kugler holds a Bachelor of Science in Materials Science and Engineering from Massachusetts Institute of Technology.